Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 28 (20) 3227-3233
Year:
2010
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
TRP
Primary Committee:
PPP
Sec. Committees:
   
Pharmas:
 
Grants:
U01 GM063340, CA-37404, N01 CA032102, U10 CA077202, U10 CA021115, U10 CA037404, CA-25224, U01-GM63340, U10 CA035101, CA-32102, U10 CA032102, N01 CA038926, U10 CA038926, R21 CA102461, CA-77202, CA-21115, CA-35101, U10 CA025224, CA-38926, R21-CA102461  
Corr. Author:
 
Authors:
                           
Networks:
 
Study
NCCTG-N9741
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Gic5, Faze, To2, To9, To15, Original Reports, Gastrointestinal Cancer